Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2014 1
2015 1
2016 1
2018 1
2019 3
2020 4
2021 10
2022 13
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Domínguez MLG, Pina JMS, Mussetti A, Sancho JM, Bastos-Oreiro M, Catala E, Delgado J, Henriquez HL, Sanz J, Calbacho M, Bailén R, Carpio C, Ribera JM, Sureda A, Briones J, Hernandez-Boluda JC, Cebrián NM, Martin JLD, Martín A, Barba P. Kwon M, et al. Among authors: bastos oreiro m. Haematologica. 2023 Jan 1;108(1):110-121. doi: 10.3324/haematol.2022.280805. Haematologica. 2023. PMID: 35770532 Free PMC article.
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.
Gonzalez Barca E, Tomás-Roca L, Esteve A, Rodriguez M, Gato L, Alonso-Alonso R, Martin Garcia-Sancho A, Cordoba R, Monter-Rovira A, Bastos-Oreiro M, Bergua Burgues JM, Sayas MJ, Viguria Alegria MC, Sanchez-Blanco JJ, Roig Pellicer M, Luzardo Henriquez HD, de Oña R, Cabezudo ME, Infante MS, Queizán Hernández JA, Sanz-Pamplona R, Blanco O, Mozos A, Climent F, Piris MA. Gonzalez Barca E, et al. Among authors: bastos oreiro m. Am J Hematol. 2023 Jun;98(6):E134-E138. doi: 10.1002/ajh.26904. Epub 2023 Mar 16. Am J Hematol. 2023. PMID: 36882876
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Among authors: bastos oreiro m. Front Immunol. 2023 Jun 5;14:1188818. doi: 10.3389/fimmu.2023.1188818. eCollection 2023. Front Immunol. 2023. PMID: 37342332 Free PMC article.
Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma.
Bastos-Oreiro M, Sanz-Villanueva L, Muñiz P, Bailén R, Chicano M, Oarbeskoa G, Gómez I, Gutiérrez A, Iglesia I, Carbonell D, Diaz-Crespo FJ, Menarguez J, Diez-Martín JL, Kwon M, Buño I, Martínez-Laperche C. Bastos-Oreiro M, et al. Transplant Cell Ther. 2023 Jul;29(7):472.e1-472.e4. doi: 10.1016/j.jtct.2023.03.009. Epub 2023 Mar 14. Transplant Cell Ther. 2023. PMID: 36921917 Free article.
Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease.
Hoyo-Muñoz A, Collado-Borrell R, Escudero-Vilaplana V, Bastos-Oreiro M, Herranz-Alonso A, Sanjurjo-Sáez M. Hoyo-Muñoz A, et al. Among authors: bastos oreiro m. J Clin Pharm Ther. 2022 Apr;47(4):548-551. doi: 10.1111/jcpt.13513. Epub 2021 Sep 12. J Clin Pharm Ther. 2022. PMID: 34514634
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti A, Bento L, Bastos-Oreiro M, Rius-Sansalvador B, Albo C, Bailen R, Barba P, Benzaquén A, Briones J, Caballero AC, Campos A, Español I, Ferra C, López SG, González Sierra PA, Guerra LM, Hernani R, Iacoboni G, Jiménez-Ubieto A, Kwon M, Corral LL, López-Godino O, Munoz MCM, Martínez-Cibrián N, Gómez JM, Pérez-Ortega L, Ortí G, Ortiz-Maldonado V, Pascual MJ, Perera M, Perez A, Reguera JL, Sanchez JM, Sanz J, Torrent A, Yáñez L, Varela R, Echechipia IC, Caballero D, Sureda A. Mussetti A, et al. Among authors: bastos oreiro m. Bone Marrow Transplant. 2023 Jun;58(6):673-679. doi: 10.1038/s41409-023-01949-x. Epub 2023 Mar 14. Bone Marrow Transplant. 2023. PMID: 36918682
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Bastos-Oreiro M, Gutierrez A, Reguera JL, Iacoboni G, López-Corral L, Terol MJ, Ortíz-Maldonado V, Sanz J, Guerra-Dominguez L, Bailen R, Mussetti A, Abrisqueta P, Hernani R, Luzardo H, Sancho JM, Delgado-Serrano J, Salar A, Grande C, Bento L, González de Villambrosía S, García-Belmonte D, Sureda A, Pérez-Martínez A, Barba P, Kwon M, Martín García-Sancho A. Bastos-Oreiro M, et al. Front Immunol. 2022 Jul 12;13:855730. doi: 10.3389/fimmu.2022.855730. eCollection 2022. Front Immunol. 2022. PMID: 35911769 Free PMC article.
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C, de Haro ME, Romero S, Gutiérrez A, Domingo-Domènech E, González-Rodríguez AP, Zeberio I, Martínez-Badas MP, Rodríguez-Izquierdo A, Carpio C, Bastos-Oreiro M, Hernández-Rivas JÁ, Vallansot R, Kelleher N, Díaz-Gálvez FJ, Torrado T, Pereira A, García-Sanz R; Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH). Martínez C, et al. Among authors: bastos oreiro m. Ann Hematol. 2023 Feb;102(2):429-437. doi: 10.1007/s00277-022-05011-6. Epub 2022 Nov 12. Ann Hematol. 2023. PMID: 36370191
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
Muntañola A, Mozas P, Mercadal S, Huguet M, Bobillo S, Bastos-Oreiro M, Jiménez-Ubieto A, Rovira J, Rivero A, Tolosa C, Luizaga L, de Villambrosia SG, Novelli S, Caballero D, Salar A, Alonso-Álvarez S, Magnano L, Gutiérrez NC, Sancho JM, López-Guillermo A; GELTAMO group (Grupo Español de Linfomas y Trasplante de Médula Ósea). Muntañola A, et al. Among authors: bastos oreiro m. Br J Haematol. 2023 Feb;200(3):306-314. doi: 10.1111/bjh.18522. Epub 2022 Oct 19. Br J Haematol. 2023. PMID: 36261137
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martín García-Sancho A, Rodríguez-García G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, González-Barca E. Katz DA, et al. Among authors: bastos oreiro m. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. doi: 10.1080/10428194.2022.2064981. Epub 2022 May 3. Leuk Lymphoma. 2022. PMID: 35503708 Free article. Clinical Trial.
50 results